Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Intravenous Infusions of E2814 in Healthy Subjects

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Intravenous Infusions of E2814 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etalanetug (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man
  • Sponsors Eisai Inc

Most Recent Events

  • 20 Jul 2023 Results assessing the safety, pharmacokinetics, and immunogenicity of single and multiple doses of E2814 in healthy subjects, presented at the Alzheimer's Association International Conference 2023.
  • 20 Jul 2023 Results evaluating in healthy (NCT04231513 )and Dominantly Inherited Alzheimers Disease (NCT04971733, n=7)participants for safety, pharmacokinetics (PK), and cerebrospinal fluid (CSF) target engagement, presented at the Alzheimer's Association International Conference 2023
  • 11 Jul 2023 According to a Eisai Co Ltd Media Release, data from this study will be presented at the Alzheimer's Association International Conference (AAIC).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top